Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech (NASDAQ: ONCY) has announced a Key Opinion Leader (KOL) webinar scheduled for July 22, 2025, at 1:00 p.m. ET. The event will focus on the company's pelareorep therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) and gastrointestinal cancers.
The webinar will feature distinguished experts including Dr. Dirk Arnold, Dr. Alexander Eggermont, Dr. Sanjay Goel, and Dr. Devalingam Mahalingam, who will join Oncolytics' management team. They will discuss existing clinical data and explore pelareorep's potential as an immunotherapy treatment. The event will include a formal presentation, roundtable discussion, and a live Q&A session.
Oncolytics Biotech (NASDAQ: ONCY) has announced transformative survival data for its immunotherapy drug pelareorep across multiple tumor types. The company reported a significant two-year survival benefit of 21.9% vs. 9.2% in pancreatic cancer (mPDAC) studies. In HR+/HER2- metastatic breast cancer trials, pelareorep demonstrated a median overall survival benefit exceeding 10 months compared to standard chemotherapy.
Key clinical achievements include a 62% objective response rate in mPDAC when combined with chemotherapy and checkpoint inhibitors. The drug's safety profile has been validated across more than 1,100 patients, showing manageable side effects. Pelareorep holds Fast Track designations for both metastatic breast cancer and mPDAC, along with Orphan Drug Designations for pancreatic cancer from both FDA and EMA.
Oncolytics Biotech (NASDAQ: ONCY) has appointed Andrew Aromando as Chief Business Officer, a strategic hire bringing over 30 years of life sciences industry experience. Aromando, who most recently served as Chief Operating Officer at Ambrx Biopharma, played a key role in the company's $2 billion acquisition by Johnson & Johnson.
In his new role, Aromando will lead global business development and contribute to corporate, clinical, and regulatory strategies. A key focus will be optimizing the value of pelareorep's clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. The company has accumulated clinical evidence from over 1,100 patients.
As part of his compensation package, Aromando received a stock option grant for 750,000 shares at CAD$0.93, vesting over three years, and 500,000 restricted stock units that vest upon specific transaction conditions related to company acquisition or pelareorep licensing.
Oncolytics Biotech (NASDAQ: ONCY) presented new data from its Phase I/II GOBLET clinical trial at the 2025 ASCO Annual Meeting, demonstrating the effectiveness of its immunotherapy drug pelareorep in treating pancreatic ductal adenocarcinoma (PDAC). The study revealed pelareorep's mechanism of action, showing how it stimulates multiple immune responses and converts immunologically cold tumors into active ones.
Key findings include pelareorep's ability to expand reovirus-specific T cells and increase cytokines and chemokines that enable anti-tumor immune responses. The GOBLET Cohort 1 trial, which evaluated pelareorep in combination with nab-paclitaxel, gemcitabine, and atezolizumab, demonstrated impressive results with a 62% overall response rate, 85% disease control rate, and 45% 12-month survival rate in first-line metastatic PDAC patients.
Oncolytics Biotech (NASDAQ: ONCY) reported its Q1 2025 financial results and clinical progress. The company's lead drug pelareorep showed promising results across multiple cancer types. Key highlights include a 33% objective response rate in anal carcinoma patients and positive safety data in pancreatic cancer trials. The company reported $15.3 million in cash and equivalents, with a net loss of $6.7 million ($0.08 per share) compared to $6.9 million ($0.09 per share) in Q1 2024. R&D expenses decreased to $4.1 million from $5.7 million year-over-year. Oncolytics secured a US$20 million share purchase agreement with Alumni Capital LP to support ongoing clinical development.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy oncology company, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the first quarter of 2025.
Participants can join through North American toll-free number (888) 510-2154 or international line (437) 900-0527, using conference ID 28038. A webcast replay will be available on the company's Investor Relations page for three months, while a dial-in replay will be accessible for one week using (888) 660-6345 (North America) or (289) 819-1450 (International) with replay code 28038#.
Oncolytics Biotech (NASDAQ: ONCY) announced it will present new data from Cohort 1 of the GOBLET study at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer.
The data will demonstrate how pelareorep activates immune responses in pancreatic cancer patients. According to Chief Medical Officer Dr. Thomas Heineman, pelareorep has shown encouraging results in multiple studies by engaging the immune system to attack pancreatic cancer tumors, potentially improving outcomes for patients with this hard-to-treat cancer.
The presentation (Abstract #2562) titled 'Role of pelareorep in activating anti-tumor immunity in PDAC' will be delivered as a poster in the Developmental Therapeutics – Immunotherapy session on June 2, 2025.
Oncolytics Biotech (NASDAQ: ONCY) has secured a strategic share purchase agreement (SPA) with Alumni Capital LP to fund the clinical development of pelareorep. The agreement provides Oncolytics with access to up to US$20 million in funding over a 15-month period.
Under the terms, Oncolytics can sell common stock to Alumni at market-based prices, maintaining full control over the timing and amount of sales. The company issued 816,326 commitment shares to Alumni and may issue an additional 816,326 shares pro rata upon purchase notices.
The common shares have received conditional listing approval on the Toronto Stock Exchange (TSX), with required notices filed with Nasdaq. The shares will be offered through a short form base shelf prospectus and prospectus supplement in accordance with securities regulations.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) was featured in a recent H.C. Wainwright Key Opinion Leader event focused on oncolytic immunotherapies in breast and pancreatic cancers. The event highlighted discussions from two prominent experts:
Dr. Martine Piccart, Honorary Professor at Université Libre de Bruxelles and Scientific Director at Institut Jules Bordet, provided insights on HR+/HER2- metastatic breast cancer and emphasized the potential of pelareorep in activating immune responses against cancer.
Dr. Alexander Eggermont, Professor at University Medical Center Utrecht, discussed current treatment standards for pancreatic ductal adenocarcinoma (PDAC) and explored pelareorep's potential impact in treating this resistant form of cancer.